Prediction of nonsentinel lymph node status in melanoma

被引:106
作者
Reeves, ME
Delgado, R
Busam, KJ
Brady, MS
Coit, DG
机构
[1] Loma Linda Univ, Dept Surg, Loma Linda, CA USA
[2] VA Med Ctr, Dept Surg, Loma Linda, CA USA
[3] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA
[4] Mem Sloan Kettering Canc Ctr, Dept Surg, Gastr & Mixed Tumor Serv, New York, NY 10021 USA
关键词
melanoma; sentinel lymph node dissection; prediction; nonsentinel lymph node;
D O I
10.1245/ASO.2003.03.020
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Most melanoma patients with a positive sentinel lymph node dissection (SLND) undergo a completion lymph node dissection (CLND) that does not yield additional positive nonsentinel lymph nodes (NSLN). This study was designed to determine if NSLN status can be predicted using patient, primary tumor, and sentinel lymph node (SLN) characteristics. Methods: The study population includes melanoma patients who had a positive SLND and subsequently underwent CLND retrieved from our prospective institutional melanoma database. The primary tumor and SLN pathologies were prospectively determined. An Size/Ulceration (SU) score was derived by assigning I point for primary tumor ulceration and 1 point for SLN tumor size >2 mm. Results: Ninety-eight patients had a positive SLND and underwent CLND. Sixteen of these patients had a positive NSLN. On univariate analysis, primary tumor characteristics (thickness, ulceration, no regression), SLN metastasis characteristics (size >2 mm, location nonsubcapsular), and SU score were all significantly associated with positive NSLN status. However, on multivariate analysis, only the SU score was a significant independent predictor of NSLN status. No patient with an SU score of 0 had a positive NSLN. Conclusions: The SU score is predictive of NSLN status in patients with a positive SLND. Patients with an SU score of 0 are very unlikely to have positive NSLNs at CLND.
引用
收藏
页码:27 / 31
页数:5
相关论文
共 28 条
[1]   Intraoperative radiolymphoscintigraphy improves sentinel lymph node identification for patients with melanoma [J].
Albertini, JJ ;
Cruse, CW ;
Rapaport, D ;
Wells, K ;
Ross, M ;
DeConti, R ;
Berman, CG ;
Jared, K ;
Messina, J ;
Lyman, G ;
Glass, F ;
Fenske, N ;
Reintgen, DS .
ANNALS OF SURGERY, 1996, 223 (02) :217-224
[2]   Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm) [J].
Balch, CM ;
Soong, SJ ;
Ross, MI ;
Urist, MM ;
Karakousis, CP ;
Temple, WJ ;
Mihm, MC ;
Barnhill, RL ;
Jewell, WR ;
Wanebo, HJ ;
Harrison, R .
ANNALS OF SURGICAL ONCOLOGY, 2000, 7 (02) :87-97
[3]  
Bilchik AJ, 1998, CANCER J SCI AM, V4, P351
[4]   Sentinel lymph node biopsy in cutaneous melanoma: The WHO Melanoma Program experience [J].
Cascinelli, N ;
Belli, F ;
Santinami, M ;
Fait, V ;
Testori, A ;
Ruka, W ;
Cavaliere, R ;
Mozzillo, N ;
Rossi, CR ;
MacKie, RM ;
Nieweg, O ;
Pace, M ;
Kirov, K .
ANNALS OF SURGICAL ONCOLOGY, 2000, 7 (06) :469-474
[5]   Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial [J].
Cascinelli, N ;
Morabito, A ;
Santinami, M ;
MacKie, RM ;
Belli, F .
LANCET, 1998, 351 (9105) :793-796
[6]  
Clopper CJ, 1934, BIOMETRIKA, V26, P404, DOI 10.2307/2331986
[7]  
COIT DG, 2002, SENTINEL LYMPH NODE, P135
[8]   Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma [J].
Gershenwald, JE ;
Colome, MI ;
Lee, JE ;
Mansfield, PF ;
Tseng, CH ;
Lee, JJ ;
Balch, CM ;
Ross, MI .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (06) :2253-2260
[9]   Multi-institutional melanoma lymphatic mapping experience: The prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients [J].
Gershenwald, JE ;
Thompson, W ;
Mansfield, PF ;
Lee, JE ;
Colome, MI ;
Tseng, CH ;
Lee, JJ ;
Balch, CM ;
Reintgen, DS ;
Ross, MI .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (03) :976-983
[10]   The progression of melanoma nodal metastasis is dependent on tumor thickness of the primary lesion [J].
Haddad, FF ;
Stall, A ;
Messina, J ;
Brobeil, A ;
Ramnath, E ;
Glass, LF ;
Cruse, CW ;
Berman, CG ;
Reintgen, DS .
ANNALS OF SURGICAL ONCOLOGY, 1999, 6 (02) :144-149